Royal Bank of Canada
SABS icon

Royal Bank of Canada’s SAB Biotherapeutics SABS Stock Holding History

Royal Bank of Canada’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+1
New +$4 ﹤0.01% 7617
2024
Q3 		– Sell
-6
Closed – – 7362
2024
Q2 		$0 Hold
6
– – ﹤0.01% 7470
2024
Q1 		$0 Sell
6
-1
-14% -$6 ﹤0.01% 7517
2023
Q4 		$0 Sell
7
-502
-99% -$4.21K ﹤0.01% 7520
2023
Q3 		$3K Sell
509
-28
-5% -$206 ﹤0.01% 6730
2023
Q2 		$4K Buy
537
+55
+11% +$450 ﹤0.01% 6748
2023
Q1 		$2K Hold
482
– – ﹤0.01% 6793
2022
Q4 		$3K Sell
482
-30
-6% -$274 ﹤0.01% 6871
2022
Q3 		$3K Buy
512
+30
+6% +$298 ﹤0.01% 6919
2022
Q2 		$7K Hold
482
– – ﹤0.01% 6528
2022
Q1 		$18K Buy
482
+282
+141% +$13K ﹤0.01% 6661
2021
Q4 		$16K Buy
200
+196
+4,900% +$18.4K ﹤0.01% 6894
2021
Q3 		$0 Buy
4
+3
+300% +$299 ﹤0.01% 7831
2021
Q2 		$0 Buy
+1
New +$99 ﹤0.01% 7653

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's SABS Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7617 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in SABS as recently as Q2 2024.

Royal Bank of Canada first reported a position in SABS in Q2 2021 and has held it in 14 quarters since. The position peaked at $18K in Q1 2022. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Royal Bank of Canada held 1 share of SAB Biotherapeutics worth $0 as of Q1 2026.
  • SAB Biotherapeutics was a new Royal Bank of Canada position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7617 holding.
  • Royal Bank of Canada first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 14 quarters since.
  • Royal Bank of Canada's SAB Biotherapeutics position peaked at $18K in Q1 2022.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.